Hard breakup of the deuteron into two Delta-isobars

We study high energy photodisintegration of the deuteron into two $\Delta$-isobars at large center of mass angles within the QCD hard rescattering model (HRM). According to the HRM, the process develops in three main steps: the photon knocks the quark from one of the nucleons in the deuteron; the struck quark rescatters off a quark from the other nucleon sharing the high energy of the photon; then the energetic quarks recombine into two outgoing baryons which have large transverse momenta. Within the HRM, the cross section is expressed through the amplitude of $pn\rightarrow \Delta\Delta$ scattering which we evaluated based on the quark-interchange model of hard hadronic scattering. Calculations show that the angular distribution and the strength of the photodisintegration is mainly determined by the properties of the $pn\rightarrow \Delta\Delta$ scattering. We predict that the cross section of the deuteron breakup to $\Delta^{++}\Delta^{-}$ is 4-5 times larger than that of the breakup to the $\Delta^{+}\Delta^{0}$ channel. Also, the angular distributions for these two channels are markedly different. These can be compared with the predictions based on the assumption that two hard $\Delta$-isobars are the result of the disintegration of the preexisting $\Delta\Delta$ components of the deuteron wave function. In this case, one expects the angular distributions and cross sections of the breakup in both $\Delta^{++}\Delta^{-}$ and $\Delta^{+}\Delta^{0}$ channels to be similar.Comment: 17 pages, 3 figure

To what extent is Gluon Confinement an empirical fact?

Experimental verifications of Confinement in hadron physics have established the absence of charges with a fraction of the electron's charge by studying the energy deposited in ionization tracks at high energies, and performing Millikan experiments with charged droplets at rest. These experiments test only the absence of particles with fractional charge in the asymptotic spectrum, and thus "Quark" Confinement. However what theory suggests is that Color is confined, that is, all asymptotic particles are color singlets. Since QCD is a non-Abelian theory, the gluon force carriers (indirectly revealed in hadron jets) are colored. We empirically examine what can be said about Gluon Confinement based on the lack of detection of appropriate events, aiming at an upper bound for high-energy free-gluon production.Comment: 14 pages, 12 figures, version accepted at Few Body Physic

Weak Gravity Conjecture and Holographic Dark Energy Model with Interaction and Spatial Curvature

In the paper, we apply the weak gravity conjecture to the holographic quintessence model of dark energy. Three different holographic dark energy models are considered: without the interaction in the non-flat universe; with interaction in the flat universe; with interaction in the non-flat universe. We find that only in the models with the spatial curvature and interaction term proportional to the energy density of matter, it is possible for the weak gravity conjecture to be satisfied.Comment: 14 pages, 7 figures, typographical errors are corrected; conclusin is unchange

Dilepton Production in Nucleon-Nucleon Reactions With and Without Hadronic Inelasticities

We calculate elementary proton-proton and neutron-proton bremsstrahlung and their contribution to the $e^+e^-$ invariant mass distribution. At 4.9 GeV, the proton-proton contribution is larger than neutron-proton, but it is small compared to recent data. We then make a first calculation of bremsstrahlung in nucleon-nucleon reactions with multi-hadron final states. Again at 4.9 GeV, the many-body bremsstrahlung is larger than simple nucleon-nucleon bremsstrahlung by more than an order of magnitude in the low-mass region. When the bremsstrahlung contributions are summed with Dalitz decay of the $\eta$, radiative decay of the $\Delta$ and from two-pion annihilation, the result matches recent high statistics proton-proton data from the Dilepton Spectrometer collaboration.Comment: 1+17 pages plus 11 PostScript figures uuencoded and appended, McGill/93-9, TPI-MINN-93/18-

Narrowing the window for millicharged particles by CMB anisotropy

We calculate the cosmic microwave background (CMB) anisotropy spectrum in models with millicharged particles of electric charge q\sim 10^{-6}-10^{-1} in units of electron charge. We find that a large region of the parameter space for the millicharged particles exists where their effect on the CMB spectrum is similar to the effect of baryons. Using WMAP data on the CMB anisotropy and assuming Big Bang nucleosynthesis value for the baryon abundance we find that only a small fraction of cold dark matter, Omega_{mcp}h_0^2 < 0.007 (at 95% CL), may consists of millicharged particles with the parameters (charge and mass) from this region. This bound significantly narrows the allowed range of the parameters of millicharged particles. In models without paraphoton millicharged particles are now excluded as a dark matter candidate. We also speculate that recent observation of 511 keV gamma-rays from the Galactic bulge may be an indication that a (small) fraction of CDM is comprised of the millicharged particles.Comment: 10 pages, 3 figures; v2: journal version, references adde

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

BackgroundInternal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia has been limited by rapid generation of resistance mutations, particularly in codon Asp835 (D835). We aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia.MethodsIn this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia who either were refractory to induction therapy or had relapsed after achieving remission with previous treatment. Patients were enrolled into one of seven dose-escalation or dose-expansion cohorts assigned to receive once-daily doses of oral gilteritinib (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg). Cohort expansion was based on safety and tolerability, FLT3 inhibition in correlative assays, and antileukaemic activity. Although the presence of an FLT3 mutation was not an inclusion criterion, we required ten or more patients with locally confirmed FLT3 mutations (FLT3mut+) to be enrolled in expansion cohorts at each dose level. On the basis of emerging findings, we further expanded the 120 mg and 200 mg dose cohorts to include FLT3mut+ patients only. The primary endpoints were the safety, tolerability, and pharmacokinetics of gilteritinib. Safety and tolerability were assessed in the safety analysis set (all patients who received at least one dose of gilteritinib). Responses were assessed in the full analysis set (all patients who received at least one dose of study drug and who had at least one datapoint post-treatment). Pharmacokinetics were assessed in a subset of the safety analysis set for which sufficient data for concentrations of gilteritinib in plasma were available to enable derivation of one or more pharmacokinetic variables. This study is registered with ClinicalTrials.gov, number NCT02014558, and is ongoing.FindingsBetween Oct 15, 2013, and Aug 27, 2015, 252 adults with relapsed or refractory acute myeloid leukaemia received oral gilteritinib once daily in one of seven dose-escalation (n=23) or dose-expansion (n=229) cohorts. Gilteritinib was well tolerated; the maximum tolerated dose was established as 300 mg/day when two of three patients enrolled in the 450 mg dose-escalation cohort had two dose-limiting toxicities (grade 3 diarrhoea and grade 3 elevated aspartate aminotransferase). The most common grade 3-4 adverse events irrespective of relation to treatment were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]), thrombocytopenia (33 [13%]), sepsis (28 [11%]), and pneumonia (27 [11%]). Commonly reported treatment-related adverse events were diarrhoea (92 [37%] of 252]), anaemia (86 [34%]), fatigue (83 [33%]), elevated aspartate aminotransferase (65 [26%]), and increased alanine aminotransferase (47 [19%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to treatment), progressive disease (43 [17%]), sepsis (36 [14%]; two related to treatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyrexia (21 [8%]; three related to treatment), bacteraemia (14 [6%]; one related to treatment), and respiratory failure (14 [6%]). 95 people died in the safety analysis set, of which seven deaths were judged possibly or probably related to treatment (pulmonary embolism [200 mg/day], respiratory failure [120 mg/day], haemoptysis [80 mg/day], intracranial haemorrhage [20 mg/day], ventricular fibrillation [120 mg/day], septic shock [80 mg/day], and neutropenia [120 mg/day]). An exposure-related increase in inhibition of FLT3 phosphorylation was noted with increasing concentrations in plasma of gilteritinib. In-vivo inhibition of FLT3 phosphorylation occurred at all dose levels. At least 90% of FLT3 phosphorylation inhibition was seen by day 8 in most patients receiving a daily dose of 80 mg or higher. 100 (40%) of 249 patients in the full analysis set achieved a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46 (18%) complete remission with incomplete haematological recovery, and 25 (10%) partial remission INTERPRETATION: Gilteritinib had a favourable safety profile and showed consistent FLT3 inhibition in patients with relapsed or refractory acute myeloid leukaemia. These findings confirm that FLT3 is a high-value target for treatment of relapsed or refractory acute myeloid leukaemia; based on activity data, gilteritinib at 120 mg/day is being tested in phase 3 trials.FundingAstellas Pharma, National Cancer Institute (Leukemia Specialized Program of Research Excellence grant), Associazione Italiana Ricerca sul Cancro

The Search for Stable, Massive, Elementary Particles

In this paper we review the experimental and observational searches for stable, massive, elementary particles other than the electron and proton. The particles may be neutral, may have unit charge or may have fractional charge. They may interact through the strong, electromagnetic, weak or gravitational forces or through some unknown force. The purpose of this review is to provide a guide for future searches - what is known, what is not known, and what appear to be the most fruitful areas for new searches. A variety of experimental and observational methods such as accelerator experiments, cosmic ray studies, searches for exotic particles in bulk matter and searches using astrophysical observations is included in this review.Comment: 34 pages, 8 eps figure

Characterizing cognitive deficits and dementia in an aging urban population in India.

Rapid rise in the population of older adults in India will lead to the need for increased health care services related to diagnosis, management, and long-term care for those with dementia and cognitive impairment. A direct approach for service provision through memory clinics can be an effective, successful, and sustaining means of delivering specialized health care services. We have established a memory clinic in Mumbai, India by employing the diverse clinical skills available in Indian academic institutions, diagnostic and research expertise of clinicians and psychologists, and the support of the U.S. National Institutes of Health. Our project involved recruitment of patients, clinical and neuropsychological assessment, and standardized diagnostic procedures, demonstrating the feasibility of using research methods to develop a memory clinic. In this paper, we describe the development of a community-based memory clinic in urban India, including linguistic and cultural factors and present detailed results, including diagnostic characterization, on 194 subjects with various stages of cognitive deficits. Our findings support the feasibility of developing a memory clinic in a public hospital and successful use of research diagnostic criteria to categorize cognitive deficits observed in this population, which may be used to inform the development of other such clinics

Measurement of Dielectric Suppression of Bremsstrahlung

In 1953, Ter-Mikaelian predicted that the bremsstrahlung of low energy photons in a medium is suppressed because of interactions between the produced photon and the electrons in the medium. This suppression occurs because the emission takes place over on a long distance scale, allowing for destructive interference between different instantaneous photon emission amplitudes. We present here measurements of bremsstrahlung cross sections of 200 keV to 20 MeV photons produced by 8 and 25 GeV electrons in carbon and gold targets. Our data shows that dielectric suppression occurs at the predicted level, reducing the cross section up to 75 percent in our data.Comment: 11 pages, format is postscript file, gzip-ed, uuencode-e